Clinical Trials Logo

Filter by:
NCT ID: NCT05533580 Recruiting - General Anesthesia Clinical Trials

Differential Effects of Remimazolam and Propofol on Dynamic Cerebral Autoregulation During General Anesthesia

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Cerebral autoregulation (CA) is the property of the cerebral vascular bed to maintain cerebral perfusion in the presence of changes in blood pressure. In the case of anesthesia, altered cerebral autoregulation, including altered carbon dioxide and hemodilution, can impair physiological changes in the body and lead to poor postoperative prognosis. As a novel ultra-short-acting benzodiazepines drugs, remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. Our study aimed to investigate the different effects of remimazolam and propofol on dynamic cerebral blood flow autoregulation function during general anesthesia.

NCT ID: NCT05533567 Recruiting - General Anesthesia Clinical Trials

Electroencephalographic Profiles During General Anesthesia: a Comparative Study of Remimazolam and Propofol

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

How anesthetic drugs induce and maintain the behavioral state of general anesthesia is an important question in medicine and neuroscience. Different anesthetic drugs act on different molecular targets and neural circuit mechanisms, exhibiting drug-specific EEG features. As a novel ultra-short-acting benzodiazepines drugs, remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aimed to investigate the differences in the characteristics of EEG oscillations during general anesthesia by comparing propofol and remimazolam.

NCT ID: NCT05533463 Recruiting - Clinical trials for Advanced KRAS G12D Mutant Solid Tumors

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Start date: September 15, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the safety and tolerability of HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation.To estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose [RP2D]) within investigated subject population groups

NCT ID: NCT05533450 Not yet recruiting - High Myopia Clinical Trials

A Study on the Efficacy and Safety of Multi-focal Scleral Contact Lens

Start date: October 18, 2022
Phase: N/A
Study type: Interventional

The rigid scleral contact lens with optical multi-focal design adopted in this study can focus the light in part of the optical area on the front of the retina to form myopic defocus, in order to delay the axial changes in children and adolescents with ultra-high myopia. In this study, RGP was used as a control, and a multicenter, randomized, controlled trial was conducted to verify the safety and effectiveness of multifocal scleral contact lenses for the correction of ultra-high myopia in children and adolescents.

NCT ID: NCT05533411 Completed - Healthy Clinical Trials

A Study of Donanemab (LY3002813) in Healthy Chinese Participants

Start date: September 14, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and tolerability of donanemab (LY3002813) when administered as single dose in healthy Chinese participants. The study will also assess how fast donanemab gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 85 days.

NCT ID: NCT05533281 Completed - Nausea and Vomiting Clinical Trials

Efficacy of Three Antiemetics in Preventing Nausea and Vomiting

Start date: September 15, 2022
Phase: Phase 4
Study type: Interventional

To explore the effect of commonly used antiemetic drugs on reducing nausea and vomiting caused by intravenous tramadol injection, so as to reduce the incidence of nausea and vomiting in clinical use of tramadol and provide guidance for the clinical use of tramadol injection

NCT ID: NCT05533203 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

Start date: August 8, 2022
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).

NCT ID: NCT05533177 Active, not recruiting - Physical Therapy Clinical Trials

Effect Analysis of Physical Therapy Based on Electronic Medical Record

Start date: March 23, 2022
Phase:
Study type: Observational

WHO has reported the heavy disease burden of psychiatric disorders. Due to the unsatisfactory effect of pharmacotherapy, physical therapy has attracted extensive attention as a complementary therapy. However, few large sample real-world studies are exploring its efficacy. This study intends to explore the efficacy of physical therapy in different types of mental disorders, which is meaningful for the formulation of personalized treatment plans.

NCT ID: NCT05533086 Recruiting - NSCLC Stage IV Clinical Trials

PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer

Start date: August 16, 2022
Phase:
Study type: Observational [Patient Registry]

Clinical trials have shown efficacy of PD1/PD-L1 checkpoint inhibitors in multiple solid tumors, including NSCLC. Whole body information with regard to target presence, drug kinetics and dynamics, as well as binding of PD-L1 targeting agents to the immune system cells is lacking.Molecular imaging of PD-L1 could lead to new insights on heterogeneity of PD-L1 expression in metastatic lesions and be of help in the prediction of response to PD1/PD-L1 inhibitors in a noninvasive manner.

NCT ID: NCT05533060 Recruiting - Clinical trials for Traumatic Brain Injury

Clinical and Molecular Biological Data Collection and Analysis in Patients With TBI

Start date: September 1, 2022
Phase:
Study type: Observational [Patient Registry]

Clinical evaluation is crucial in the clinical diagnosis, treatment, and prognosis prediction in patients with traumatic brain injury (TBI). However, the existing evaluation systems are not perfect, because many factors are not taken into account, for example, there is a lack of molecular diagnostic criteria for evaluating patients with TBI. We attempt to collect the patient's clinical data and combine it with neuroimaging, as well as molecular biomarkers generated by single-cell sequencing to assess their neurological status and outcome. The clinical and molecular data collection and analysis will be helpful to evaluate the patient's neurological condition and predict the patient's outcome more accurately.